BCM
CRBP icon

Bayesian Capital Management’s Corbus Pharmaceuticals CRBP Stock Holding History

Bayesian Capital Management’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-555
Closed -$91K – 803
2019
Q4 		$91K Buy
+555
New +$82K 0.02% 567

Other funds holding CRBP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bayesian Capital Management's CRBP Position: Q1 2020 in Review

Bayesian Capital Management sold out of Corbus Pharmaceuticals (CRBP) in Q1 2020, closing a stake of 555 shares — an estimated $91K sold.

Bayesian Capital Management first reported a position in CRBP in Q4 2019 and held it in 1 quarter. The position peaked at $91K in Q4 2019. 111 funds tracked by Wall St. Rank hold CRBP as of Q1 2020.

  • Bayesian Capital Management reported no remaining Corbus Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Bayesian Capital Management sold 555 Corbus Pharmaceuticals shares in Q1 2020, an estimated $91K.
  • Bayesian Capital Management first reported a position in Corbus Pharmaceuticals in Q4 2019 and held it in 1 quarter.
  • Bayesian Capital Management's Corbus Pharmaceuticals position peaked at $91K in Q4 2019.
  • 111 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q1 2020.

Based on Bayesian Capital Management's 13F filing for Q1 2020, filed 15 May 2020.